Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s): QNTM

Healthcare

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

CSE:QNTM - Post by User

Quantum BioPharma Ltd

<< Previous

Bullboard Posts

Next >>

Post by DavidRosenbergon Sep 29, 2021 2:37pm

81 Views

Post# 33937917

FSD Pharma Info

FSD Pharma Growth Strategy

Pursue further acquisition targets or potential investments that are unique and align with our mission of Total Brain Health
Begin the process of advancing clinical trials for its compound Lucid-21-302, for the novel treatment of progressive MS (Multiple Sclerosis)
Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-201
Assess the best path forward for the advancement of FSD-201
Complete the sale of our Cobourg property to increase cash in a non-dilutive method

Lucid Acquisition

FSD Pharma acquired Lucid in September 2021
Two unique pre-clinical lead drug candidates aimed to treat neurodegenerative diseases and neuropsychiatric disorders
- LUCID-21-302 – target treatment: Multiple Sclerosis
- LUCID-201 – target treatment: depression & anxiety
New Chemical Entities (NCEs) with patents licensed from UHN (largest healthcare research organization in NA) and uniquely paired with psychedelics formulations to improve patient outcomes
Large addressable markets: $23B¹ multiple sclerosis market and growing multibillion-dollar mental health market

FSD-201: Ultra Micro-PEA Compound

Proprietary ultra micro-PEA formulation enhances the anti-inflammatory properties of PEA, a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy- making it suitable to treat a range of inflammatory conditions
Holds exclusive worldwide licensing rights (except Italy & Spain) to ultra micro-PEA for all conditions in all regulatory categories
Strong IP portfolio covering ultra-micronized composition of matter and use (2029-34 U.S. expiration)
- Lead candidate (FSD 201- 600mg ultra micro-PEA)
- Successfully completed Phase 1 first-in-human safety and tolerability trial. No serious adverse effects discovered
- Toxicology trials have been completed and the results are being compiled
Potential Target indications for Phase 2 trials currently being analyzed

Growing Market Opportunity in Psychedelics

Growing body of research that suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety

FDA approval of Johnson & Johnson’s SPRAVATO (esketamine) for treatment-resistant depression

Meaningful MAPS Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment

Expanding pipeline of psychedelic-based therapies